Literature DB >> 10026019

Adverse events during treatment with high-dose intravenous immunoglobulins for neurological disorders.

M Stangel1, M Müller, P Marx.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 10026019     DOI： 10.1159/000007976

Source DB:  PubMed          Journal:  Eur Neurol        ISSN： 0014-3022            Impact factor:   1.710


× No keyword cloud information.
  2 in total

1.  Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study.

Authors:  Eric Hachulla; Gwendal Le Masson; Guilhem Solé; Mohamed Hamidou; Claude Desnuelle; Jean-Philippe Azulay; Gérard Besson; Laure Swiader; Sébastien Abad; Jean-Christophe Antoine; Françoise Bouhour; Alain Créange; Marike Grenouillet; Laurent Magy; Sébastien Marcel; Jean-Michel Paquet; François Rouhart; François Ziegler; Stéphane Mathis; Marc Gauthier-Darnis; Sophie Puget
Journal:  Biomed Res Int       Date:  2018-03-15       Impact factor: 3.411

2.  Acute flaccid paralysis and West Nile virus infection.

Authors:  James J Sejvar; A Arturo Leis; Dobrivoje S Stokic; Jay A Van Gerpen; Anthony A Marfin; Risa Webb; Maryam B Haddad; Bruce C Tierney; Sally A Slavinski; Jo Lynn Polk; Victor Dostrow; Michael Winkelmann; Lyle R Petersen
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.